JPWO2021142257A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142257A5 JPWO2021142257A5 JP2022542216A JP2022542216A JPWO2021142257A5 JP WO2021142257 A5 JPWO2021142257 A5 JP WO2021142257A5 JP 2022542216 A JP2022542216 A JP 2022542216A JP 2022542216 A JP2022542216 A JP 2022542216A JP WO2021142257 A5 JPWO2021142257 A5 JP WO2021142257A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- human subject
- composition according
- bone marrow
- marrow cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025186533A JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| US62/958,632 | 2020-01-08 | ||
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186533A Division JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023509968A JP2023509968A (ja) | 2023-03-10 |
| JPWO2021142257A5 true JPWO2021142257A5 (https=) | 2024-01-17 |
| JP2023509968A5 JP2023509968A5 (https=) | 2024-01-17 |
| JP7771064B2 JP7771064B2 (ja) | 2025-11-17 |
Family
ID=76788747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542216A Active JP7771064B2 (ja) | 2020-01-08 | 2021-01-08 | 脾腫を治療する方法 |
| JP2025186533A Pending JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186533A Pending JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3980069A4 (https=) |
| JP (2) | JP7771064B2 (https=) |
| KR (1) | KR20220130151A (https=) |
| CN (1) | CN114423457A (https=) |
| AU (1) | AU2021205484A1 (https=) |
| BR (1) | BR112022013646A2 (https=) |
| CA (1) | CA3164063A1 (https=) |
| CO (1) | CO2022010592A2 (https=) |
| CR (1) | CR20220374A (https=) |
| IL (1) | IL294582A (https=) |
| JO (1) | JOP20220168A1 (https=) |
| MA (3) | MA63848B1 (https=) |
| MX (1) | MX2022008490A (https=) |
| TN (1) | TN2022000185A1 (https=) |
| WO (1) | WO2021142257A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980069A4 (en) * | 2020-01-08 | 2022-08-17 | Telios Pharma, Inc. | METHODS OF TREATMENT OF SPLENOMEGALY |
| US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| IL309238A (en) * | 2021-06-16 | 2024-02-01 | Telios Pharma Inc | Treatment of symptoms associated with myeloproliferative tumors |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| CN119677518A (zh) * | 2022-08-25 | 2025-03-21 | 百济神州(苏州)生物科技有限公司 | 包含(s)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺和草酸的固体形式、其组合物及其使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| MA40596B1 (fr) * | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN112313214A (zh) * | 2018-06-19 | 2021-02-02 | 默克专利有限公司 | 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法 |
| CN109942835A (zh) * | 2019-03-27 | 2019-06-28 | 广州楹鼎生物科技有限公司 | 一种催化分解木质纤维原料的方法 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| EP3980069A4 (en) * | 2020-01-08 | 2022-08-17 | Telios Pharma, Inc. | METHODS OF TREATMENT OF SPLENOMEGALY |
-
2021
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 MA MA63848A patent/MA63848B1/fr unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 TN TNP/2022/000185A patent/TN2022000185A1/en unknown
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 JP JP2022542216A patent/JP7771064B2/ja active Active
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko active Pending
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en not_active Ceased
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MA MA69153A patent/MA69153A1/fr unknown
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
-
2022
- 2022-07-07 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
-
2025
- 2025-11-05 JP JP2025186533A patent/JP2026027353A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| IL294582A (en) | Methods for treating an enlarged spleen | |
| TWI241911B (en) | Sustained release ranolazine formulations | |
| KR20230145439A (ko) | Irak4 분해제 및 이의 용도 | |
| JP2021523220A5 (https=) | ||
| JP5948246B2 (ja) | Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法 | |
| US20080032989A1 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| JP2019503365A5 (https=) | ||
| CN1350454A (zh) | 阿朴吗啡和西地拉非组合物 | |
| EA037152B1 (ru) | Способ лечения рака | |
| TW200904430A (en) | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye | |
| JPWO2022269525A5 (https=) | ||
| JPWO2021142257A5 (https=) | ||
| CA2677470A1 (en) | Methods of treatment using eszopiclone | |
| JP2019537615A (ja) | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 | |
| TWI302912B (en) | Therapeutic use | |
| JPWO2020132210A5 (https=) | ||
| WO2020238932A1 (zh) | Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途 | |
| JPWO2021260111A5 (https=) | ||
| JPWO2019213074A5 (https=) | ||
| US6333345B1 (en) | Methods of using and compositions comprising N-desmethylzolpidem | |
| JPWO2022254371A5 (https=) | ||
| CN116847842A (zh) | Irak4降解剂和其用途 | |
| CN109875999B (zh) | 泊那替尼在kit突变型恶性黑色素瘤中的应用 | |
| JPWO2021260109A5 (https=) |